Most anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancers (NSCLCs) are
highly responsive to treatment with ALK tyrosine kinase inhibitors (TKIs). However, patients …

Activating BRAF kinase mutations arise in ∼7% of all human tumors, and preclinical studies
have validated the RAF–mitogen-activated protein/extracellular signal-regulated kinase (…

Kinase inhibitors constitute an important new class of cancer drugs, whose selective
efficacy is largely determined by underlying tumor cell genetics. We established a high-throughput …

Purpose: Cyclin-dependent kinase 9 (CDK9) is a transcriptional regulator and potential
therapeutic target for many cancers. Multiple nonselective CDK9 inhibitors have progressed …

Pancreatic ductal adenocarcinoma (PDAC) is resistant to most therapies including single-agent
immunotherapy and has a dense desmoplastic stroma, and most patients present with …

Deregulation of the PRC2 complex, comprised of the core subunits EZH2, SUZ12, and EED,
drives aberrant hypermethylation of H3K27 and tumorigenicity of many cancers. Although …

To find a reason that the world needs both more taxonomists and better training for them,
mammalogist Michael Mares, director of the Sam Noble Oklahoma Museum of Natural History, …

De novo variation in SCN2A can give rise to severe childhood disorders. Biophysical gain
of function in SCN2A is seen in some patients with early seizure onset developmental and …

MCL-1 and BCL-2 are both frequently overexpressed in acute myeloid leukemia (AML) and
critical for the survival of AML cells and AML stem cells. MCL-1 is a key factor in venetoclax …

We have synthesized three peptides from the mdm-2 binding domain of human p53, residues
12–26 (PPLSQETFSDLWKLL), residues 12–20, and 17–26. To enable transport of the …